Odyssey Therapeutics — Third Quarter 2026 Earnings Summary

Odyssey Therapeutics reported third-quarter 2026 financial results showing a net loss of $53.1 million and $387 million in cash reserves expected to fund operations through the second half of 2028. The company advanced its pipeline with additional Phase 2a induction data for OD-001 in ulcerative colitis that reinforced clinical proof of concept, completed IND-enabling studies for the SLC15A4 inhibitor OD-002, and nominated a development candidate for the TSLP/IL-33 bispecific antagonist OD-004. Leadership changes included the appointment of Anthony Opipari as chief medical officer and Laura Hare as chief people officer to support continued clinical development. Upcoming milestones include top-line results for OD-001 trials in the second half of 2027 and the initiation of a Phase 1/2a trial for OD-002 in the first half of 2027.